Recent Updates
Recently added Catalysts
ACAD Positive Sentiment

Acadia Pharmaceuticals to Present Remlifanserin Data at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference

Monday, November 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Acadia Pharmaceuticals announced it will present data on remlifanserin at the 2026 CTAD conference. The presentations will focus on findings from the Phase 2 portion of the RADIANT clinical trial program. This event is scheduled for November 16-19, 2026, in Boston, highlighting the company's ongoing research in Alzheimer's disease psychosis.

Market Sentiment Analysis

POSITIVE FACTORS

  • Acadia will present new data on remlifanserin.
  • The presentations will focus on Alzheimer's disease psychosis.
  • The event will take place at a prominent conference in Boston.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
6.4%
average across 10 past catalysts
Lead asset
ACP-211
Phase 2 · Major Depressive Disorder (MDD)

Full Press Release Details

SAN DIEGO, Calif.--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present two data presentations related to Alzheimer's disease psychosis (ADP) and remlifanserin at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place November 16-19, 2026, in Boston. Acadia's presentations include an oral presentation featuring findings from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin in patients

Frequently Asked Questions

What is the focus of Acadia's presentations?

The presentations will focus on Alzheimer's disease psychosis and remlifanserin.

When will the CTAD conference take place?

The CTAD conference is scheduled for November 16-19, 2026.

What trial data will be presented?

Data from the Phase 2 portion of the RADIANT clinical trial will be presented.

Where is the CTAD conference being held?

The conference will be held in Boston.

ShareAdd on Google
Tags: ACAD Acadia Pharmaceuticals remlifanserin Alzheimer's disease CTAD 2026 clinical trial
Last updated: Nov 9, 2026

Biotech snapshot

Cash runway
$976M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ACP-211Phase 2
Major Depressive Disorder (MDD) →

Catalyst track record

+24%
best trade around ACAD's most recent catalyst

Peak hindsight return over a 120-day window, across 10 tracked FDA/PDUFA catalysts for ACAD.

See every catalyst's timing & PoA →